Endometriosis as a pathology of regulatory mechanisms
article
OA: hybrid
CC0
⤵ 7 in-corpus citations
Abstract
The article represents the author’s original definition of genital endometriosis, emphasizing the main pathogenetic feature of the disease — violation of regulatory mechanisms, underlying in its development and characterizing diversity of its pathogenetic and clinical forms. The hierarchy of regulatory mechanisms is given, general ideas concerning approaches to the study of this illness and approaches to drug therapy are described. Special attention is paid to immunomodulatory therapy in patients with endometriosis, critical analysis of its advantages and disadvantages is given, and prospects of this direction are demonstrated.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (2)
- W2205256798 via openalex
- W2405567958 via openalex
Cited by (7)
- Approaches to the search for immunological markers of endometriosis and the degree of its prevalence 2025
- Prospects for Using 3D Modeling and Biomarkers in Differential Diagnosis of Endometrioid Ovarian Cysts 2024
- The role of systemic and local immunity in the pathogenesis of endometriosis of varying degrees of prevalence of the process: a modern view 2024
- Immunological factor development of external genital endometriosis 2023
- Problems of chronic pelvic pain in modern gynecology 2023
- Role of genes involved in the regulation of apoptosis in the pathogenesis of genital endometriosis. A literature review 2021
- Sensitive periods in development of endometriosis 2018
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK